PLATELET RESPONSE KINETICS WITH IANALUMAB PLUS ELTROMBOPAG VS ELTROMBOPAG ALONE IN SECOND-LINE PRIMARY IMMUNE THROMBOCYTOPENIA: A RANDOMIZED, DOUBLE-BLIND, PHASE 3 VAYHIT2 STUDY (SIE 2026) - Oct 6, 2026 - Abstract #C076; Pres time: Sep 22, 2026; 03:40 PM - 05:10 PM; Location: HALL 4; P3 | "N Engl J Med. 2025.Disclosure: This study was Funded by Novartis."
Clinical • P3 data • Hematological Disorders • Immune Thrombocytopenic Purpura • Thrombocytopenia • Thrombocytopenic Purpura
|
|
F. Zaja1; H. Al-Samkari2; N. Cooper3; M. Crysandt4; W. Ghanima5,6; M. Michel7; T. Stauch8; R. Wong9; M. Weill10; P. Urban10; J. Fronczek10; M. Foster11; A. Cuker12
|